B1Q Panoramica delle azioni NRx Pharmaceuticals, Inc. è un'azienda biofarmaceutica in fase clinica che sviluppa nuovi farmaci per il trattamento dei disturbi del sistema nervoso centrale, tra cui la depressione suicidaria, il disturbo da stress post-traumatico e il dolore cronico. Maggiori dettagli
Premi Analisi del rischio + 1 più rischio
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
NRx Pharmaceuticals, Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per NRx Pharmaceuticals Prezzi storici delle azioni Prezzo attuale dell'azione US$1.21 Massimo di 52 settimane US$6.55 Minimo di 52 settimane US$1.21 Beta 1.08 Variazione di 1 mese 0% Variazione a 3 mesi -6.20% Variazione di 1 anno n/a Variazione a 3 anni -97.21% Variazione a 5 anni n/a Variazione dall'IPO -99.37%
Notizie e aggiornamenti recenti
NRx Pharmaceuticals, Inc. Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression Dec 30
NRx Pharmaceuticals, Inc. Announces Chief Financial Officer Changes Nov 19
NRx Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 08
NRx Pharmaceuticals, Inc. Announces Chief Executive Officer Changes Oct 12
NRx Pharmaceuticals, Inc., Annual General Meeting, Oct 08, 2024 Aug 28
NRx Pharmaceuticals, Inc. Announces Resignation of Stephen Willard as Chief Executive Officer Aug 23 Vedi altri aggiornamenti
NRx Pharmaceuticals, Inc. Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression Dec 30
NRx Pharmaceuticals, Inc. Announces Chief Financial Officer Changes Nov 19
NRx Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 08
NRx Pharmaceuticals, Inc. Announces Chief Executive Officer Changes Oct 12
NRx Pharmaceuticals, Inc., Annual General Meeting, Oct 08, 2024 Aug 28
NRx Pharmaceuticals, Inc. Announces Resignation of Stephen Willard as Chief Executive Officer Aug 23
NRx Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 14, 2024 Aug 14
NRx Pharmaceuticals Receives Letter from the Listing Qualifications Staff of the Nasdaq Regarding Market Value of Listed Securities Aug 13
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Announce Alignment with FDA on Pediatric Study Plan for NRX-100 (ketamine) Jul 29
NRx Pharmaceuticals, Inc. to Proceed with Two New Drug Applications in 2024 Jun 28
NRx Pharmaceuticals, Inc. Appoints Dennis McBride to Its Board of Directors Jun 18
NRx Pharmaceuticals, Inc. Presents Landmark Trial of Nrx-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: Nrx-101 Is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression May 29
NRx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024 May 09
NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results May 08
NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression May 01
NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression Apr 30 NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.0031 million. Apr 20
NRx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering. NRx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering. Apr 18
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics Apr 17
NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) Apr 16
NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression Apr 09 NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing Mar 29
NRx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 28, 2024 Mar 22
Less than half of directors are independent Mar 07
NRX Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression Mar 05 NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million. Feb 28
NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.
Panel Grants NRx Pharmaceuticals Request for an Exception to Nasdaq Listing Rules Until April 16, 2024, to Demonstrate Compliance with the Rule Jan 24
NRx Pharmaceuticals, Inc. Announces Completion of Enrollment of Its Phase 2b/3 Trial of NRx-101 in Suicidal Treatment Resistant Bipolar Depression Jan 23
NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis Jan 16
NRx Pharmaceuticals Demonstrates Compliance with Nasdaq MVLS Standard Jan 02
Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors Dec 27
NRx Pharmaceuticals, Inc. Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections Dec 18
NRx Pharmaceuticals, Inc., Annual General Meeting, Dec 19, 2023 Nov 23
NRx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023 Nov 08
NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain Oct 28
NRx Pharmaceuticals Receives Formal Notice from the Listing Qualifications Staff of Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Oct 24
NRx Pharmaceuticals Announces Strategic Acceleration of its Plans to Develop Commercial Form of NRX-100 (intravenous ketamine) to Treat Acute Depression and Suicidality Oct 13
NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain Oct 05 NRX Pharmaceuticals, Inc. Appoints Richard Narido, as Principal Financial Officer and Principal Accounting Officer
NRx Pharmaceuticals, Inc. Announces New Data That Demonstrates Potent in Vitro Activity of NRx-101 Sep 07
NRx Pharmaceuticals Announces Submission of an Investigational New Drug Application for NRX -101 in the Treatment of Chronic Pain Aug 31 NRx Pharmaceuticals, Inc. announced that it expects to receive $1.2 million in funding Aug 30
NRx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 08
NRx Pharmaceuticals Receives Written Notification from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(b)(2)(A) – Market Value of Listed Securities Jul 30
NRx Pharmaceuticals, Inc. Reports Minutes of U.S. Food and Drug Administration Meeting on Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality Feb 14
NRx Pharmaceuticals, Inc. Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101 Jan 20
NRx Pharmaceuticals, Inc. Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted Jan 04
Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc. Dec 22
Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements Dec 20
NRx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022 Nov 11 NRx Pharmaceuticals, Inc. Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process Nov 10
NRx Pharmaceuticals, Inc. announced that it has received $10 million in funding Nov 09
NRx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 15, 2022 Aug 11
NRx Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Jul 16 NRx Pharmaceuticals, Inc. Announces the Appointment of Stephen Willard as its Chief Executive Officer
Nrx Pharmaceuticals, Inc. Announces FDA Declines Emergency Use Authorization for Zyesami® (Aviptadil) for Subgroup of Patients with Critical Covid-19 At Immediate Risk of Death from Respiratory Failure Despite Treatment with Approved Therapy, Including Remdesivir Jul 02
High number of new and inexperienced directors Jun 25
NRx Pharmaceuticals, Inc. Announces Class Action Suit Against the Company Dismissed Jun 23
Nrx Pharmaceuticals, Inc. Announces Director Resignation Jun 22
NRx Pharmaceuticals, Inc., Annual General Meeting, Jul 18, 2022 Jun 17
NRx Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Denied for aviptadil Jun 14
NRx Pharmaceuticals, Inc. Provides Update on Breakthrough Therapy Designation Request for ZYESAMI® (Aviptadil) Jun 11
NRx Pharmaceuticals Appoints Seth Van Voorhees as Chief Financial Officer, Effective June 13, 2022 Jun 08
Co-Founder recently bought €54k worth of stock Jun 04 NRx Pharmaceuticals, Inc. Announces Executive Changes
NRx Pharmaceuticals, Inc. Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19 May 27 Rendimenti per gli azionisti B1Q DE Pharmaceuticals DE Mercato 7D 0% 3.4% 2.0% 1Y n/a -14.7% 9.6%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: Dati insufficienti per determinare come si è comportato B1Q rispetto al settore German Pharmaceuticals.
Rendimento vs Mercato: Dati insufficienti per determinare la performance di B1Q rispetto al mercato German.
Volatilità dei prezzi Is B1Q's price volatile compared to industry and market? B1Q volatility B1Q Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di B1Q è stato volatile rispetto al mercato German.
Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di B1Q nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 2015 n/a Jonathan Javitt www.nrxpharma.com
NRx Pharmaceuticals, Inc. è un'azienda biofarmaceutica in fase clinica che sviluppa nuovi farmaci per il trattamento dei disturbi del sistema nervoso centrale, tra cui la depressione suicidaria, il disturbo da stress post-traumatico e il dolore cronico. I suoi prodotti includono NRX-101 (D-cicloserina/Lurasidone), una combinazione orale a dosaggio fisso di D-cicloserina e lurasidone che ha ottenuto la designazione di terapia innovativa da parte della Food and Drug Administration per la depressione bipolare resistente al trattamento dei suicidi; e NRX-100 (ketamina), che ha ottenuto la designazione fast track da parte della FDA per il trattamento della depressione bipolare grave con ideazione e comportamento suicida acuti. L'azienda ha una partnership con Alvogen Inc. e Lotus Pharmaceutical Company; un accordo di sviluppo e produzione con Nephron Pharmaceuticals, Inc. e Alcami; un accordo di licenza con Apkarian Technologies; un accordo di sviluppo e licenza con Glytech; un accordo di licenza con il Sarah Herzog Memorial Hospital.
Mostra di più NRx Pharmaceuticals, Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di NRx Pharmaceuticals con la sua capitalizzazione di mercato? B1Q statistiche fondamentali Capitalizzazione di mercato €40.70m Guadagni(TTM ) -€19.60m Ricavi(TTM ) n/a
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) B1Q Conto economico (TTM ) Ricavi US$0 Costo del fatturato US$0 Profitto lordo US$0 Altre spese US$20.39m Guadagni -US$20.39m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -1.69 Margine lordo 0.00% Margine di profitto netto 0.00% Rapporto debito/patrimonio netto -32.1%
Come si è comportato B1Q nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/07 08:14 Prezzo dell'azione a fine giornata 2024/10/25 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche NRx Pharmaceuticals, Inc. è coperta da 3 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Edward Woo Ascendiant Capital Markets LLC Jason Kolbert D. Boral Capital LLC. Vernon Bernardino H.C. Wainwright & Co.
Mostra 0 altri analisti 